Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]

Breast conservation therapy

Prof Virgilio Sacchini - European Institute of Oncology, Milan, Italy

Breast conservation therapy ( Prof Virgilio Sacchini - European Institute of Oncology, Milan, Italy )

Improving care for cancer patients

Dr David Hui - MD Anderson Cancer Center, Houston, USA

Improving care for cancer patients ( Dr David Hui - MD Anderson Cancer Center, Houston, USA )

Managing cancer and living meaningfully

Dr Gary M. Rodin - UHN Princess Margaret Hospital, Toronto, Canada

Managing cancer and living meaningfully ( Dr Gary M. Rodin - UHN Princess Margaret Hospital, Toronto, Canada )

Treating the patient, not the disease: in memory of Umberto Veronesi

Prof Gordon McVie - Editor in Chief, ecancer

Treating the patient, not the disease: in memory of Umberto Veronesi ( Prof Gordon McVie - Editor in Chief, ecancer )

Clinical potential of trastuzumab biosimilar CTP6

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA

Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )

ASCO 2017: Round up

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ASCO 2017: Round up ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

Adding a second HER2 targeted medicine may lower chance of invasive breast...

Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer ( Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Targeted sequencing in endocrine refractory breast cancer

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

$Targeted sequencing in endocrine refractory breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )$

Results from the APHINITY trial of two HER2 targeted agents with chemo

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Results from the APHINITY trial of two HER2 targeted agents with chemo ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Treating BRCA breast cancer with PARP inhibition

Dr Mika Sovak - AstraZeneca, Cambridge, UK

Treating BRCA breast cancer with PARP inhibition ( Dr Mika Sovak - AstraZeneca, Cambridge, UK )

Phase III results of olaparib for BRCA breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

More from ecancer